Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2020 Jul;190(2):149-172.
doi: 10.1111/bjh.16504. Epub 2020 Mar 6.

Emerging therapies in sickle cell disease

Amina Nardo-Marino  1 , Valentine Brousse  2 , David Rees  3
Affiliations
Review

Emerging therapies in sickle cell disease

Amina Nardo-Marino et al. Br J Haematol. 2020 Jul.

Abstract

Despite sickle cell disease (SCD) being the most common and severe inherited condition worldwide, therapeutic options are limited. To date, hydroxyurea remains the main treatment option in SCD. However, in the last decade the numbers of interventional clinical trials focussing on therapies for SCD have increased significantly. Many new drugs with various pharmacological targets have emerged and, although the majority have failed to show benefit in clinical trials, some have produced encouraging results. It seems probable that more drugs will soon become available for the treatment of SCD. Furthermore, promising clinical trials with improved outcomes have recently changed the perspective of curative therapies in SCD. Nevertheless, the application of novel therapeutic agents and potential curative treatments will most likely be limited to high-income countries and, thus, will remain unavailable for the majority of people with SCD in the foreseeable future.

Keywords: clinical trials; gene editing; hydroxyurea; inflammation; sickle cell disease.

PubMed Disclaimer

References

    1. Adamkiewicz, T.V., Szabolcs, P., Haight, A., Baker, K.S., Staba, S., Kedar, A., Chiang, K.Y., Krishnamurti, L., Boyer, M.W., Kurtzberg, J., Wagner, J.E., Wingard, J.R. & Yeager, A.M. (2007) Unrelated cord blood transplantation in children with sickle cell disease: review of four-center experience. Pediatric Transplantation, 11, 641-644.
    1. Angelucci, E., Matthes-Martin, S., Baronciani, D., Bernaudin, F., Bonanomi, S., Cappellini, M.D., Dalle, J.H., di Bartolomeo, P., de Heredia, C.D., Dickerhoff, R., Giardini, C., Gluckman, E., Hussein, A.A., Kamani, N., Minkov, M., Locatelli, F., Rocha, V., Sedlacek, P., Smiers, F., Thuret, I., Yaniv, I., Cavazzana, M. & Peters, C. (2014) Hematopoietic stem cell transplantation in thalassemia major and sickle cell disease: indications and management recommendations from an international expert panel. Haematologica, 99, 811-20.
    1. Ataga, K.I., Smith, W.R., de Castro, L.M., Swerdlow, P., Saunthararajah, Y., Castro, O., Vichinsky, E., Kutlar, A., Orringer, E.P., Rigdon, G.C. & Stocker, J.W. (2008) Efficacy and safety of the Gardos channel blocker, senicapoc (ICA-17043), in patients with sickle cell anemia. Blood, 111, 3991-3997.
    1. Ataga, K.I., Reid, M., Ballas, S.K., Yasin, Z., Bigelow, C., James, L.S., Smith, W.R., Galacteros, F., Kutlar, A., Hull, J.H., Stocker, J.W. & Investigators, I.C.A.S. (2011) Improvements in haemolysis and indicators of erythrocyte survival do not correlate with acute vaso-occlusive crises in patients with sickle cell disease: a phase III randomized, placebo-controlled, double-blind study of the Gardos channel blocker senicapoc (ICA-17043). British Journal of Haematology, 153, 92-104.
    1. Ataga, K.I., Kutlar, A., Kanter, J., Liles, D., Cancado, R., Friedrisch, J., Guthrie, T.H., Knight-Madden, J., Alvarez, O.A., Gordeuk, V.R., Gualandro, S., Colella, M.P., Smith, W.R., Rollins, S.A., Stocker, J.W. & Rother, R.P. (2017) Crizanlizumab for the prevention of pain crises in sickle cell disease. New England Journal of Medicine, 376, 429-439.

MeSH terms

Substances

LinkOut - more resources